Literature DB >> 7945307

Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.

K Bojanowski1, K Nishio, M Fukuda, A K Larsen, N Saijo.   

Abstract

We examined the effect of suramin, an anticancer agent and a functional analog of naturally occuring glycosaminoglycans, on p34cdc2 kinase. We find that suramin strongly inhibits the catalytic activity of purified p34cdc2 kinase (IC50 approximately 4 microM), whereas it only weakly inhibits the p13-agarose precipitated kinase activity from nuclear and cytoplasmic extracts of the asynchronous H69 human small cell lung cancer cells. We also find that the tyrosine phosphorylation of p34cdc2 kinase in the nuclear extract is increased about twice when the extracts are preincubated with 50 microM of suramin prior to the p13-agarose precipitation. We propose that this increase might result from the inhibitory effect of suramin towards p34cdc2-specific tyrosine phosphatases. These results suggest both a direct and an indirect effect of suramin on p34cdc2 kinase. We also find that heparin is a potent inhibitor of purified cdc2 kinase (IC50 approximately 3.5 micrograms/ml). Therefore, glycosaminoglycans might be physiological regulators of p34cdc2 kinase in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945307     DOI: 10.1006/bbrc.1994.2366

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

2.  CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer.

Authors:  Sayantan Bhattacharyya; Vasanthakumar Sekar; Biswanath Majumder; Debapriya G Mehrotra; Samir Banerjee; Anup K Bhowmick; Neyaz Alam; Gautam K Mandal; Jaydip Biswas; Pradip K Majumder; Nabendu Murmu
Journal:  Cell Oncol (Dordr)       Date:  2016-12-30       Impact factor: 6.730

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.